BMS Signs a Clinical Trial Collaboration with NeoImmune to Evaluate Opdivo (nivolumab) in Combination with NT-I7 (Hyleukin-7)

Bristol-Myers (BMS) Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-II CheckMate -650 trial for Metastatic Castration-Resistant Prostate Cancer (mCRPC)


  • NeoImmuneTech to sponsor the trial and BMS will supply Opdivo (nivolumab) for the use in the trial. Additionally, under Master Clinical Trial Collaboration Agreement, the first study will be focusing on gastric/GEJ/EAC cancers and the companies can evaluate additional combination trials in the future
  • The goal of the collaboration is to evaluate preliminary anti-tumor activity of the combination of Opdivo + NT-I7 in P-II trial assessing the safety and tolerability to treat advanced or metastatic gastric, GEJ, or EAC in patients
  • NT-I7 (also known as Hyleukin-7) is a long-acting human IL-7 and is evaluated in multiple clinical trials in solid tumors, and being planned for testing in hematologic malignancies and other immunology-focused indications

Click here ­to­ read full press release/ article | Ref:  Business Wire  | Image: BMS